MarketInOut Stock Screener Log In | Sign Up
 

Allergy Therapeutics Plc

LSE • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 10/23/2026
Allergy Therapeutics Plc stock price and volume chart

Company Profile

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeLSE
Market Capitalization284.96 mln
Float745 mln
Earnings Date03/04/2027

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-3.53
Highly reliable

Relative Strength

5 / 100
Severely lagging

Debt / Equity

6.30
Extremely leveraged

Pre-Tax Margin

-82%
Severely loss-making

ROE

409
Extraordinary

Business Description

Allergy Therapeutics plc is a UK-based biotechnology company founded in 1998 that specializes in treating and diagnosing allergic conditions across Europe and beyond. The company offers a range of established allergy treatments, including injections and oral therapies targeting reactions to pollen, insect venom, and dust mites. It is also advancing two promising pipeline products: a grass pollen immunotherapy and a short-course peanut allergy vaccine.

Key Fundamentals

EPS-1.00
ROE409
RPS0.01
ROIC-73.91
ROA-69.45
Interest Cover-4.41
EBITDA, mln-34.63
EV / EBITDA-6.26
EV / EBIT-5.55
Revenue, mln57.29
EV / Revenue3.78

Quote Details

Last 4.27
Change -0.23 (-5.11%)
Open 5.00
Volume 5,328
Turnover 22,751
Average Volume 86,762

Financial Ratios

Pre-Tax Profit Margin-82
Leverage Ratio16.71
Current Ratio1.13
Price / Book47.50
Debt / Equity6.30
Price / Sales4.32

Financial Strength

Altman Z-Score-2.85
Piotroski F-Score 2 / 9
Beneish M-Score-3.53

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.11% 13 / 100   
1 Month -11.41% 11 / 100   
2 Months -34.31% 3 / 100   
6 Months -60.83% 1 / 100   
1 Year -47.93% 5 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog